1300 856 695
+44 203 514 0688
1800 867 1390If you would like to submit a blog post for consideration, please email admin@healthcert.com
Research Review on Dermatology [February 3]
A phase 2 dose-escalation RCT comparing three strengths of sirolimus gel and placebo for facial angio bromas in the tuberous sclerosis complex begins this research review on dermatology. This is followed by a randomised trial demonstrating the bene cial effects of NB-UVB (narrow-band UVB) and PUVA (psoralen plus UVA) in managing steroid-dependent, antihistamine-refractory chronic urticaria. In other RCTs included, IVIG (intravenous immunoglobulin) was found to be bene cial in the treatment of steroid-resistant bullous pemphigoid, as was gabapentin for haemodialysis patients with uraemic pruritus.
Featured in this issue:
- Topical sirolimus for facial angiofibromas in the tuberous sclerosis complex
- NB-UVB and PUVA beneficial in severe chronic urticaria
- Statins increase herpes zoster risk
- Maculopapular exanthema and DRESS overlap among cutaneous adverse drug reactions
- IVIG for bullous pemphigoid
- Rosacea and GI disorders
- Treating/preventing atopic eczema: analysis of systematic reviews from 2014
- Ingenol mebutate gel for clearing AKs
- Low-histamine diet for chronic spontaneous urticaria
- Gabapentin in haemodialysis patients with uraemic pruritus
Click here to download the full paper
Interested in General Dermatology?
The HealthCert Professional Diploma of General Dermatology will teach you how to manage all major dermatological conditions in primary care. The courses are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The program is delivered online.
1300 856 695
+44 203 514 0688
1800 867 1390
